Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics: results from single oral dose studies in healthy volunteers Ghent University
Aims: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of odanacatib (ODN), a cathepsin K inhibitor, in humans. Methods: Two double-blind, randomized, placebo-controlled, single oral dose studies were performed with ODN (2600mg) in 44 healthy volunteers (36 men and eight postmenopausal women). Results: Adverse experiences (AEs) with single doses of ODN were transient and mild to moderate, with the exception of one ...